Human Microbiome Project

NEW RESEARCH PAPER SUPPORTS USING MICROBIOME DATA TO DEVELOP POTENTIAL PROBIOTIC THERAPIES

Retrieved on: 
Thursday, January 26, 2023

CLEVELAND, Jan. 26, 2023  /PRNewswire/ -- In a new paper, published Jan. 25, 2023, online by the journal Gastroenterology, researchers from University Hospitals (UH) Cleveland Medical Center and Case Western Reserve University School of Medicine, review studies about the microbiome's role in disease and health, and discuss tactics for developing probiotics to modulate the microbiome through leveraging microbiome data. They illustrate these tactics by using Crohn's disease (CD) as an example.

Key Points: 
  • The comprehensive intestinal microbiome, representing bacterial and fungal communities, profiles were assessed at the start of the study and following four weeks of probiotic consumption.
  • Through the analysis of big microbiome data sets, researchers have started to appreciate the microbiome composition differences between different cohorts of individuals.
  • That has lead to the opportunity to leverage such data insights for targeted microbiome solution development.
  • The probiotic formulation developed through this data-powered design process was launched in market by BIOHM Health Inc. as a general wellness probiotic.

Worldwide Human Microbiome Industry to 2028 - Players Include Seres Therapeutics, 4D Pharma, OptiBiotix Health and Synlogic - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022

The Global Human Microbiome Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 32.2% CAGR during the forecast period.

Key Points: 
  • The Global Human Microbiome Market size is expected to reach $1.1 billion by 2028, rising at a market growth of 32.2% CAGR during the forecast period.
  • The efficiency of medicinal drugs is significantly influenced by the microbiome of the human gut.
  • Several studies have demonstrated that the appropriate balance of microorganisms in the human body can help treat a variety of ailments over time.
  • This link between bacteria and specific diseases may open up new possibilities for drug developers (or vaccine manufacturers).

CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University

Retrieved on: 
Tuesday, July 27, 2021

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
  • The ability to study the human microbiome and its effects on human health is an area of great research interest and a pivotal application for OOC technology.
  • Modelling the human microbiome in the laboratory is challenging, especially since many of its several thousand strains of bacteria cannot grow or survive when exposed to oxygen.
  • Dr David Hughes, CEO, CN Bio, commented: We are rapidly coming to appreciate the important role the microbiome plays in human health and disease.

DERMALA, A Consumer Dermatology Company, Announces Issuance of A New U.S. Patent Covering Human Microbiome to Treat and Prevent Acne

Retrieved on: 
Wednesday, June 23, 2021

This patent covers using the human microbiome to treat and prevent acne.Acneis the eighthmost prevalent disease worldwide and the most common skin condition.

Key Points: 
  • This patent covers using the human microbiome to treat and prevent acne.Acneis the eighthmost prevalent disease worldwide and the most common skin condition.
  • DERMALA's patented technology uses novel, human microbiome-derived postbiotics, metabolites derived from beneficial bacteria in the human microbiome, that inhibit acne-causingC.
  • Using the human microbiome to treat skin conditions associated with microbiome imbalances makes great scientific sense.
  • DERMALA, Inc. is a consumer dermatology company leveraging a scientific understanding of the human microbiome and data analytics to develop novel solutions for acne and other skin conditions.

Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD)

Retrieved on: 
Tuesday, June 22, 2021

"Our platform enables Second Genome to analyze large and complex clinical data sets, and to discover and develop precision therapies and biomarkers for heterogenous diseases where the microbiome plays an important role, such as IBD.

Key Points: 
  • "Our platform enables Second Genome to analyze large and complex clinical data sets, and to discover and develop precision therapies and biomarkers for heterogenous diseases where the microbiome plays an important role, such as IBD.
  • This approach offers numerous advantages, including detection of microbial signatures consistent in multiple cohorts that we believe reflect the biologically relevant signals in human health and disease.
  • These genes were used to generate compound libraries for screening to identify molecules that modulate T cell cytokines important in IBD.
  • Peptides predicted to be differentially associated with IBD were identified with activity on primary human T cell production of regulatory IL-10 and/or pathogenic IL-17 cytokines.

Phase Genomics Releases Platform for Discovering New Viruses in Microbiome Samples

Retrieved on: 
Tuesday, June 15, 2021

Phase Genomics, the global leader in proximity-ligation based genomic solutions, today announced the launch of a new platform aimed at the discovery of viral genomes from complex microbiome samples.

Key Points: 
  • Phase Genomics, the global leader in proximity-ligation based genomic solutions, today announced the launch of a new platform aimed at the discovery of viral genomes from complex microbiome samples.
  • Phase Genomics has published the method and several datasets demonstrating the new capabilities of the ProxiMeta Metagenome Deconvolution Platform to bioRxiv .
  • The new method is integrated into Phase Genomics microbiome discovery platform, ProxiMeta , and is now available in conjunction with Phase Genomics reagent kits and sample prep services.
  • ABOUT PHASE GENOMICS Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture.

Healthy Microbiome Designed by Gusto Global Shows Promise to Radically Change Treatment for Inflammatory Diseases

Retrieved on: 
Wednesday, June 9, 2021

Gusto Global , a leading microbiome discovery platform company focused on restoring a healthy microbiome, has developed novel consortia of bacteria that shows promise as a breakthrough therapy for treating Crohns disease and ulcerative colitis in patients.

Key Points: 
  • Gusto Global , a leading microbiome discovery platform company focused on restoring a healthy microbiome, has developed novel consortia of bacteria that shows promise as a breakthrough therapy for treating Crohns disease and ulcerative colitis in patients.
  • Crohns disease and ulcerative colitis are both forms of inflammatory bowel diseases (IBD).
  • Gusto Globals deep characterization of microbiomes and clear therapeutic design thinking represent the frontier of microbiome innovation.
  • Founded in 2016, Gusto Global is the leading microbiome discovery platform company focused on understanding the dynamics of human microbial ecosystems and developing targeted solutions.

Second Genome to Present Big Data Analytics Capabilities at the Microbiome Data Congress

Retrieved on: 
Wednesday, June 9, 2021

"With Odessa's fast speed, built-in quality controls and scale of data processing, coupled with a full suite of analytics and machine learning tools, Second Genome has built the world's largest curated and harmonized microbial genomics database which has multiple discovery applications for Second Genome and its collaborators," said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome.

Key Points: 
  • "With Odessa's fast speed, built-in quality controls and scale of data processing, coupled with a full suite of analytics and machine learning tools, Second Genome has built the world's largest curated and harmonized microbial genomics database which has multiple discovery applications for Second Genome and its collaborators," said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome.
  • Odessa allows us to not only keep pace with the rapid growth of available microbiome sequence data but also contextualize the data to optimize biomarker targeting and other discovery initiatives."
  • Odessa's built-in exploratory data analysis tools, including metagenomic and differentially expressed gene analysis, also enable more efficient data visualization and analysis.
  • We also collaborate with industry, academic and governmental partners to leverage our microbiome platform and data science.

Illumina and Microba Life Sciences Partner to Accelerate Microbiome Research

Retrieved on: 
Monday, May 24, 2021

Illumina, Inc., the global leader in DNA sequencing and array-based technologies, announced today it united with leaders in precision gut microbiome science Microba Life Sciences to advance understanding of the human gut microbiome in human health and disease.

Key Points: 
  • Illumina, Inc., the global leader in DNA sequencing and array-based technologies, announced today it united with leaders in precision gut microbiome science Microba Life Sciences to advance understanding of the human gut microbiome in human health and disease.
  • Microba CEO Mr Blake Wills said the partnership would further accelerate the adoption of gut microbiome profiling for research into human disease.
  • There remains huge potential for research to enhance our understanding of the role the gut microbiome plays in health and disease states, he said.
  • Microba Life Sciences is a precision microbiome science company working to transform human health through their world-leading technology in analysing the microbiome.

Human Microbiome Market worth $1,598 million by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, March 16, 2021

the human microbiome research spending marketgrowth is largely driven by the increasing focus on the development of human microbiome therapy.

Key Points: 
  • the human microbiome research spending marketgrowth is largely driven by the increasing focus on the development of human microbiome therapy.
  • Based on application, the human microbiome market is segmented into therapeutics and diagnostics.
  • The infectious diseases segment is expected to account for the largest share of the global human microbiome market in 2024.
  • North America is expected to account for the largest share of the global human microbiome research spending market in 2019.